JP7148415B2 - タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫 - Google Patents

タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫 Download PDF

Info

Publication number
JP7148415B2
JP7148415B2 JP2018568203A JP2018568203A JP7148415B2 JP 7148415 B2 JP7148415 B2 JP 7148415B2 JP 2018568203 A JP2018568203 A JP 2018568203A JP 2018568203 A JP2018568203 A JP 2018568203A JP 7148415 B2 JP7148415 B2 JP 7148415B2
Authority
JP
Japan
Prior art keywords
toxoplasma
protein
nucleic acid
toxoplasma gondii
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018568203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525744A (ja
JP2019525744A5 (enExample
Inventor
オーデッド レチャヴィ
シャハール ブラチャ
リラチ シャイナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Ramot at Tel Aviv University Ltd
Original Assignee
University of Glasgow
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Ramot at Tel Aviv University Ltd filed Critical University of Glasgow
Publication of JP2019525744A publication Critical patent/JP2019525744A/ja
Publication of JP2019525744A5 publication Critical patent/JP2019525744A5/ja
Priority to JP2022151508A priority Critical patent/JP7497397B2/ja
Application granted granted Critical
Publication of JP7148415B2 publication Critical patent/JP7148415B2/ja
Priority to JP2024087211A priority patent/JP7748681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/05—Carbon-nitrogen ligases with glutamine as amido-N-donor (6.3.5)
    • C12Y603/05005—Carbamoyl-phosphate synthase (glutamine-hydrolysing) (6.3.5.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018568203A 2016-06-29 2017-06-29 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫 Active JP7148415B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022151508A JP7497397B2 (ja) 2016-06-29 2022-09-22 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
JP2024087211A JP7748681B2 (ja) 2016-06-29 2024-05-29 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355898P 2016-06-29 2016-06-29
US62/355,898 2016-06-29
PCT/IL2017/050731 WO2018002938A1 (en) 2016-06-29 2017-06-29 Engineered parasites for delivering protein to the central nervous system (cns)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022151508A Division JP7497397B2 (ja) 2016-06-29 2022-09-22 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫

Publications (3)

Publication Number Publication Date
JP2019525744A JP2019525744A (ja) 2019-09-12
JP2019525744A5 JP2019525744A5 (enExample) 2020-07-27
JP7148415B2 true JP7148415B2 (ja) 2022-10-05

Family

ID=60786743

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018568203A Active JP7148415B2 (ja) 2016-06-29 2017-06-29 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
JP2022151508A Active JP7497397B2 (ja) 2016-06-29 2022-09-22 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
JP2024087211A Active JP7748681B2 (ja) 2016-06-29 2024-05-29 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022151508A Active JP7497397B2 (ja) 2016-06-29 2022-09-22 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
JP2024087211A Active JP7748681B2 (ja) 2016-06-29 2024-05-29 タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫

Country Status (8)

Country Link
US (3) US11260081B2 (enExample)
EP (1) EP3478301A4 (enExample)
JP (3) JP7148415B2 (enExample)
KR (1) KR102513120B1 (enExample)
CN (1) CN109757100A (enExample)
AU (1) AU2017289886A1 (enExample)
CA (1) CA3028334A1 (enExample)
WO (1) WO2018002938A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3028334A1 (en) 2016-06-29 2018-01-04 Ramot At Tel-Aviv University Ltd. Engineered parasites for delivering protein to the central nervous system (cns)
IL278213B2 (en) * 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
CN109369796A (zh) * 2018-09-27 2019-02-22 华中农业大学 一种检测羊弓形虫IgG抗体的酶联免疫方法
CN110117609B (zh) * 2019-05-20 2023-06-02 安徽农业大学 一种真菌基因敲除双荧光筛选方法
EP3976071A1 (en) * 2019-05-29 2022-04-06 Université de Tours Toxoplasma platform for treating cancer
BR112021024636A2 (pt) * 2019-06-10 2022-01-18 Infectious Disease Res Inst Métodos e composições de replicons de astrovírus
EP4007814A1 (en) * 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
MX2022011177A (es) * 2020-03-11 2022-12-13 Massachusetts Eye & Ear Infirmary Terapia genica para la degeneracion de la retina asociada a nmnat1.
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
KR102561980B1 (ko) * 2021-03-16 2023-08-01 한양대학교 에리카산학협력단 톡소포자충 gra9 단백질 또는 상기 단백질을 암호화하는 유전자를 유효성분으로 포함하는, 염증성 질환 예방 또는 치료용 약학적 조성물
CN116139259B (zh) * 2021-11-19 2026-07-03 中国医学科学院药物研究所 Timp2在制备预防或治疗创伤性脑损伤药物中的应用
CN114524869B (zh) * 2022-01-25 2023-06-09 华中农业大学 弓形虫微线体蛋白MIC17a及其应用
KR102834734B1 (ko) * 2022-04-28 2025-07-16 경희대학교 산학협력단 톡소포자충의 항원 rop4를 포함하는 재조합 백시니아 바이러스 백신
US20260097087A1 (en) * 2022-09-23 2026-04-09 Novome Biotechnologies, Inc. Recombinant fusion polypeptides for secreting soluble, heterologous cargo
CN121406674A (zh) * 2022-10-08 2026-01-27 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
CN121941701A (zh) * 2023-07-28 2026-04-28 特兰埃克斯公司 用于治疗溶酶体病症的突变tfeb
EP4560316A1 (en) * 2023-11-23 2025-05-28 Biokit Research & Development S.L.U. Antigenic regions for the detection of anti-toxoplasma gondii igm antibodies
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用
WO2025235741A1 (en) * 2024-05-09 2025-11-13 Grann Pharmaceuticals Inc. Compositions and methods for modulating mecp2 activity
CN119925428B (zh) * 2025-04-07 2025-07-11 天津捷昂康生物科技发展有限公司 一种树突状细胞在预防和/或治疗脱髓鞘疾病中的应用
CN120424771B (zh) * 2025-07-08 2025-10-17 华中农业大学 弓形虫mic19基因敲除虫株及其构建方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046321A1 (en) 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US8293224B2 (en) 2000-02-07 2012-10-23 Trustees Of Dartmouth College Attenuated uracil auxotroph of an apicomplexan and use thereof
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
JP2006518184A (ja) * 2002-09-20 2006-08-10 アクゾ・ノベル・エヌ・ベー 弱毒寄生虫生ワクチン
US9757440B2 (en) 2007-10-29 2017-09-12 Trustees Of Dartmouth College Method for treating cancer with Toxoplasma gondii vaccine
CA3028334A1 (en) 2016-06-29 2018-01-04 Ramot At Tel-Aviv University Ltd. Engineered parasites for delivering protein to the central nervous system (cns)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046321A1 (en) 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Koshy, A. A. et al.，"Toxoplasma secreting Cre recombinase for analysis of host-parasite interactions"，Nat. Methods，2010年，Vol. 7，pp. 307-309
Sommerville, C. et al.，"Biochemical and Immunological Characterization of Toxoplasma gondii Macrophage Migration Inhibitory Factor"，J. Biol. Chem.，2013年，Vol. 288，pp. 12733-12741
Wang, Y. et al.，"Research advances in microneme protein 3 of Toxoplasma gondii"，Parasit. Vectors，2015年，Vol. 8; 384，pp. 1-12

Also Published As

Publication number Publication date
US11260081B2 (en) 2022-03-01
EP3478301A4 (en) 2020-04-22
AU2017289886A1 (en) 2019-01-24
US20250057892A1 (en) 2025-02-20
JP2022184996A (ja) 2022-12-13
CA3028334A1 (en) 2018-01-04
JP2024112982A (ja) 2024-08-21
US20200121731A1 (en) 2020-04-23
JP2019525744A (ja) 2019-09-12
EP3478301A1 (en) 2019-05-08
KR102513120B1 (ko) 2023-03-27
US20220160790A1 (en) 2022-05-26
US12070476B2 (en) 2024-08-27
WO2018002938A1 (en) 2018-01-04
JP7497397B2 (ja) 2024-06-10
JP7748681B2 (ja) 2025-10-03
CN109757100A (zh) 2019-05-14
KR20190021339A (ko) 2019-03-05

Similar Documents

Publication Publication Date Title
JP7497397B2 (ja) タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
US12006508B2 (en) Methods and products for expressing proteins in cells
KR20170009464A (ko) 헤마글루티닌-뉴라미니다아제와 f 단백질을 과발현하는 중간엽줄기세포 및 그 용도
CN118715322A (zh) 酶、复合体、重组载体、遗传性疾病治疗药以及多核苷酸
JP2022531930A (ja) 栄養要求性調節可能な細胞を使用する方法および組成物
US20250320461A1 (en) Genetically modified human stem cell expressing a mutant human cytochrome p450 2b6 protein and its use thereof in the treatment of cancer
JP2008120740A (ja) Ｃｄ８ｔ細胞活性化抑制剤、それを用いたリウマチ治療薬およびリウマチ治療用ｄｎａワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200611

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20210423

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220922

R150 Certificate of patent or registration of utility model

Ref document number: 7148415

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250